CorMedix Inc. (NYSEAMERICAN:CRMD) CEO Khoso Baluch bought 104,166 shares of CorMedix stock in a transaction on Tuesday, December 12th. The stock was purchased at an average price of $0.48 per share, with a total value of $49,999.68. Following the completion of the acquisition, the chief executive officer now directly owns 225,373 shares of the company’s stock, valued at approximately $108,179.04. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

CorMedix Inc. (CRMD) traded up $0.01 on Friday, hitting $0.58. 1,290,000 shares of the stock traded hands, compared to its average volume of 980,524. CorMedix Inc. has a 12-month low of $0.32 and a 12-month high of $2.48.

Institutional investors and hedge funds have recently bought and sold shares of the company. Elliott Management Corp increased its holdings in shares of CorMedix by 177.8% during the second quarter. Elliott Management Corp now owns 4,166,868 shares of the biotechnology company’s stock valued at $1,785,000 after acquiring an additional 2,666,668 shares in the last quarter. Susquehanna International Group LLP increased its holdings in shares of CorMedix by 11,785.4% during the second quarter. Susquehanna International Group LLP now owns 2,067,973 shares of the biotechnology company’s stock valued at $886,000 after acquiring an additional 2,085,670 shares in the last quarter. Sabby Management LLC acquired a new position in shares of CorMedix during the second quarter valued at about $1,818,000. Finally, Vanguard Group Inc. increased its holdings in shares of CorMedix by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 35,148 shares in the last quarter.

CRMD has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of CorMedix from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Friday, September 8th. HC Wainwright set a $4.00 target price on shares of CorMedix and gave the stock a “buy” rating in a report on Monday, October 16th.

ILLEGAL ACTIVITY WARNING: “CorMedix Inc. (CRMD) CEO Acquires $49,999.68 in Stock” was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.watchlistnews.com/cormedix-inc-crmd-ceo-acquires-49999-68-in-stock/1769987.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Insider Buying and Selling by Quarter for CorMedix (NYSEAMERICAN:CRMD)

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.